Pfizer Inc.played a sound strategy testing its pan-HER inhibitor dacomitinib in non-small cell lung cancer – including studying it against market-leading Tarceva – but the failure of two Phase III trials are still a blow for Pfizer’s oncology pipeline.
Pfizer Oncology Pipeline Takes Hit With Dacomitinib Lung Failure
Expectations for the asset hadn’t been high, but failure of two Phase III lung cancer studies of the irreversible pan-HER inhibitor dacomitinib may remove a potential competitor for Boehringer Ingelheim’s recently approved irreversible EGFR inhibitor Gilotrif.
More from Clinical Trials
More from R&D
• By
Aragen’s CEO Manni Kantipudi, who is keenly watching the Trump Administration’s moves on pharma tariffs, discusses funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, and talks with the Indian government to solve intellectual property challenges in an interview.
• By
The European Medicines Agency’s chief, Emer Cooke, explained how the agency could help companies with their drug development plans, and said the EU Health Technology Assessment Regulation would help companies design clinical trials that are fit for regulators and HTA bodies.
• By
Pharmaceutical companies need to “pressure test” their clinical development strategies early for health technology assessment purposes, particularly in light of the new EU HTA Regulation, a life sciences consultant says.